PERK/EIF2AK3: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of PERK/EIF2AK3. The page also collects GeneMedi's different modalities and formats products for PERK in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the PERK target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Introcelluar Protein.
The protein encoded by this gene phosphorylates the alpha subunit of eukaryotic translation-initiation factor 2, leading to its inactivation, and thus to a rapid reduction of translational initiation and repression of global protein synthesis. This protein is thought to modulate mitochondrial function. It is a type I membrane protein located in the endoplasmic reticulum (ER), where it is induced by ER stress caused by malfolded proteins. Mutations in this gene are associated with Wolcott-Rallison syndrome. [provided by RefSeq, Sep 2015]
|Gene Symbol and Synonyms||EIF2AK3,PEK,PERK,WRS|
|Uniprot Entry Name||E2AK3_HUMAN,E2AK3_RAT|
|Protein Sub-location||Introcelluar Protein|
|Category||Therapeutics Target, Immuno-oncology Target|
|Target Classification||Checkpoint-Immuno Oncology|
Pre-made anti-PERK inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-PERK monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-PERK mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Antibody Name||Species||Format||Classified by tag||Detail|
|Anti-PERK/EIF2AK3 monoclonal antibody||Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine||mab||Therapeutics Target antibody||Detail|
Recombinant multi-species E2AK3/ PERK/ EIF2AK3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine PERK/EIF2AK3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
|Products Name||Species||Expression Platform||Detail|
|PERK/EIF2AK3 protein||Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine||Mammalian cell||Detail|